THE VALUE OF PROSTATE HEALTH INDEX (PHI) TO DIAGNOSE PROSTATE CANCER
Main Article Content
Abstract
Background: Prostate cancer is the most common cancer in men. According to Globocan 2018, the incidence and death rate of this cancer are 2nd and 5th, respectively, among the 10 most common cancers for men in the world. In Vietnam, prostate cancer is 5th among 10 common cancers for men. Many studies in the world have shown prostate health index (PHI), a new biological that can predict the progression of prostate tumors, so promise high value to diagnose prostate cancer. Objectives: (1) Determine the value of prostate health index to diagnose prostate cancer. (2) Find out the correlation between prostate health index and histopathological results (Gleason score). Materials and methods: A cross-sectional descriptive study was conducted of 84 patients with doubtful diagnosis of prostate cancer. Patients have had examined clinical signs, taken ultrasound, tumor biopsy and histopathological testing. Results: PHI has an area under the ROC curve of 0.958 (CI 95%: 0.916-1.000). At the PHI cutoff ≥ 50.2, the sensitivity and specificity are 93.5% and 98.1%, respectively to diagnose prostate cancer on doubtful patients. PHI didn’t correlate with Gleason score (r = 0.314; p = 0.085). Conclusion: PHI can be a good indicator to diagnose prostate cancer.
Keywords
prostate cancer, p2PSA test, PHI
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Nguyễn Thị Duyên (2018), Đánh giá giá trị nồng độ p2PSA huyết thanh và chỉ số PHI trong ung thư biểu mô tuyến tiền liệt. Luận văn thạc sỹ y học. Đại Học Y Hà Nội.
3. Nguyễn Ngọc Rạng (2012), Ứng dụng đường cong ROC. Thiết Kế Nghiên Cứu & Thống Kê Y Học, Nhà xuất Bản Y Học.
4. Abdelgadir A.E., Haala M.G., Ghada A., et al (2014), Use of free to total prostate-specific antigen ratio to improve differentiation of prostate cancer from benign prostate hyperplasia. Egyptian Academic Journal of Biological Sciences, 6(1), pp 151-156.
5. Bray F., Ferlay J., et al (2018), Global cancer statistics 2018: Globocan Estimates of Incedence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 68, pp 394-424.
6. Calle C., Patil D., Wei J.T., et al (2015), Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. Journal of Urology, 194(1), pp 65-72.
7. Cheng Y.T., Chiang C.H., et al (2018), The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center. Journal of The Formosan Medical Association, pp 1-8.
8. Chiu P.K., et al (2016), Prostate Health Index and %p2PSA Predict Aggressive Prostate Cancer Pathology in Chinese Patients Undergoing Radical Prostatectomy. Ann Surg Oncol.
9. Beckman Coulter (2018), Access Hybritech p2PSA. Instruction For Use, USA.
10. Beckman Coulter (2018), Access Hybritech PSA. Instruction For Use, USA.
11. Beckman Coulter (2018), Access Hybritech Free PSA. Instruction For Use, USA.
12. Filella X., Foj L. (2014), Clinical utility of %p2PSA and Prostate Health Index in the detection of prostate cancer. Clin Chem Lab Med, 52(9), pp 1347-1355.